Market
Maca extract in China is supplied through a value chain that expanded after maca (Lepidium meyenii) was introduced and cultivated in Yunnan, with Lijiang frequently cited as a major production base. Research on Yunnan maca production describes a rapid sector build-up and subsequent downturn after the mid-2010s boom, implying demand- and policy-sensitive volatility for maca-derived ingredients. In-market use is primarily as a botanical input for functional products; when positioned as “health food” (dietary supplement) in China, product registration/filing and labeling/claim controls apply. For international B2B trade, buyers commonly emphasize authenticity, contaminant control, and documentation alignment to the destination’s rules.
Market RoleDomestic producer and processor with mixed domestic consumption and ingredient export participation
Domestic RoleBotanical ingredient used in functional food and health-food product formulations, with demand historically showing boom–bust characteristics in Yunnan maca sector development
Market GrowthMixed (2010s sector development context)boom–bust cycle described for Yunnan maca sector, with a sharp expansion followed by contraction after the mid-2010s
Risks
Regulatory Compliance HighMarket access can be blocked or severely disrupted if maca extract is positioned or labeled inconsistently with China’s applicable regulatory pathway (e.g., ordinary food ingredient vs “health food”/dietary supplement), or if required registration/filing and claim controls are not met.Lock the intended use category early; align formulation, labeling, and claims to SAMR requirements for health foods when applicable, and keep a compliance dossier for audits and buyer reviews.
Authenticity MediumBuyer rejection risk increases when identity/marker testing and origin substantiation are weak, especially given the history of rapid sector expansion and market volatility around Yunnan maca production.Use a clear specification with agreed analytical methods and batch COAs; implement supplier qualification and traceability to cultivation/processing lots.
Food Safety MediumBotanical extracts can face elevated scrutiny for contaminants (e.g., heavy metals, pesticide residues, microbiological contamination) depending on the destination and intended use category.Adopt a risk-based testing plan tied to cultivation area and process controls; provide third-party lab reports where required by buyers.
Market Volatility MediumHistorical boom–bust dynamics in Yunnan maca sector development can translate into supply and price instability, affecting contract performance and long-term sourcing plans.Diversify approved suppliers and maintain safety stock policies; use contracts with quality and delivery contingencies.
Logistics LowWhile freight intensity is low, port disruptions and humidity exposure in transit can cause delays or quality loss (caking/off-odor) in powder shipments.Specify moisture-barrier packaging and desiccant use; plan longer lead times during disruption periods and use QA checks on arrival.
Sustainability- Land-use and ecological management concerns linked to rapid cash-crop expansion and subsequent adjustments in Yunnan (Lijiang) maca production during the 2010s.
Labor & Social- Smallholder livelihood exposure to boom–bust price dynamics reported for Yunnan maca sector development and downturn after the mid-2010s.
FAQ
Which Chinese authorities are most relevant for compliance if a maca extract product is sold as a dietary supplement (“health food”)?In China, “health food” products follow the registration/filing framework administered by the State Administration for Market Regulation (SAMR). Food-safety standards and “new food materials” administration sit under the National Health Commission (NHC) system, and customs clearance is handled by the General Administration of Customs (GACC).
What is the single biggest deal-breaker risk for maca extract market access in China?The biggest blocker is regulatory misalignment: if the product’s positioning (ordinary food ingredient vs “health food”), labeling, or claims do not match the applicable SAMR pathway, market access can be delayed, refused, or disrupted.